Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

doi:10.1158/1535-7163.MCT-07-2232

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

Molecular cancer therapeutics - 1 Jul 2008

Gonzales Andrea J, Hook Kenneth E, Althaus Irene W, Ellis Paul A, Trachet Erin, Delaney Amy M, Harvey Patricia J, Ellis Teresa A, Amato Danielle M, Nelson James M, Fry David W, Zhu Tong, Loi Cho-Ming, Fakhoury Stephen A, Schlosser Kevin M, Sexton Karen E, Winters R Thomas, Reed Jessica E, Bridges Alex J, Lettiere Daniel J, Baker Deborah A, Yang Jianxin, Lee Helen T, Tecle Haile, Vincent Patrick W

Abstract excerpt

Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments. PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to ErbB Receptors

Share to Mice, SCID

Share to Phosphorylation

Share to Quinazolinones

Share to Receptor Protein-Tyrosine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 18606718
DOI: 10.1158/1535-7163.MCT-07-2232

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.PMID 18606718Read ↗

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.Semantic proximity Read ↗

Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors.Semantic proximity Read ↗

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to GefitinibSemantic proximity Read ↗

SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.Semantic proximity Read ↗

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.Semantic proximity Read ↗

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancerSemantic proximity Read ↗

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read ↗

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.Semantic proximity Read ↗

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.Semantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects.Semantic proximity Read ↗

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.